Neuraxis, Inc. (NRXS) Dividend History

Company News

• NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025

  NeurAxis, Inc. will report its Q1 2025 financial results on May 12, 2025, before market open, and host a conference call on the same day at 9:00 am ET to review the results.

  GlobeNewswire Inc.
• NeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025

  NeurAxis, a medical technology company, will report its Q4 and fiscal year 2024 financial results on March 20, 2025, and host a conference call to discuss the results.

  GlobeNewswire Inc.
• UPDATE - NeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Across Multiple States

  NeurAxis, a medical technology company, announced that its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, IB-Stim, has received medical policy coverage from a prominent insurer with approximately 5.1 million members across 13 states.

  GlobeNewswire Inc.
• NeurAxis Inc. Issues Letter to Shareholders

  NeurAxis, a medical technology company, announced its achievements in 2024, including the growth of IB-Stim for pediatric irritable bowel syndrome and the commercialization of RED, a screening tool for chronic constipation. The company also highlighted its plans to submit for expanded indications in 2025 and its focus on revenue growth, cost management, and balance sheet strengthening.

  GlobeNewswire Inc.
• NeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

  NeurAxis, a medical technology company, announced that CEO Brian Carrico will participate in a webcasted company presentation at the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025. The company is focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults.

  GlobeNewswire Inc.